Document is current
Any future updates will be listed below
-
Authors
Zanwar, Saurabh https://orcid.org/0000-0001-5074-8453
Kumar, Shaji https://orcid.org/0000-0001-5392-9284
Rajkumar, S. Vincent https://orcid.org/0000-0002-5862-1833
- License Information
-
More Information
Article History
Accepted: 7 January 2026
First Online: 22 January 2026
Competing interests
: S.K. has acted as a consultant or adviser (with all payments made to his institution) for AbbVie, Bristol Myers Squibb/Celgene, Genentech/Roche, Janssen Oncology/Johnson & Johnson, K36, Pfizer, Regeneron, Sanofi and Takeda; declares research funding (to his institution) from AbbVie, Allogene Therapeutics, Bristol Myers Squibb/Celgene, CARsgen Therapeutics, GlaxoSmithKline, Janssen Oncology/Johnson & Johnson, MedImmune, Novartis, Regeneron, Roche/Genentech, Sanofi and Takeda; and has received reimbursement for travel, accommodation and expenses from AbbVie, Beigene, Janssen/Johnson & Johnson and Pfizer. S.V.R. is Chair of the International Myeloma Foundation Board of Directors; has received honoraria for CME Lectures for Medscape; declares intellectual property and royalties as an author and section editor for UpToDate (covering topics on plasma cell disorders); and served as principal investigator of the AQUILA trial, and in that capacity has also presented on behalf of Johnson & Johnson to the FDA ODAC in support of the approval of daratumumab for high-risk smouldering multiple myeloma. S.Z. declares no competing interests.
